News & Updates

Progression-free (PFS) and overall survival (OS) are similar between age groups (≥70 and <70 years) among  patients treated with cyclin-dependent kinase (CDK) 4/6 inhibitors from 2015 to 2019, with no significant differences in neutropaenia or thrombocytopaenia toxicity, reports a study.

An earlier onset of fever appears to predict a more severe and progressive cytokine release syndrome, a life-threatening hyper-inflammatory state caused by immune effector cell therapy, suggests a study. Such condition also warrants several doses of anti-interleukin (IL)-6 therapy, such as tocilizumab.

Treatment with proton therapy reirradiation for head and neck cancer appears to improve survival outcomes in patients, but this benefit comes with substantial toxic effects, according to a study.

Childhood cancer survivors (CCS) appear to have an increased risk of low bone mineral density (BMD) and fracture compared with the general population, according to a cross-sectional study from the Netherlands.

The use of immune checkpoint inhibitors (ICIs) for the treatment of various cancers appears to have hepatotoxic effects, the risk of which is greater with ICI combination therapy than with monotherapy, as reported in a recent study.